Valuation: BioNTech SE

Market Cap 20.2B 23.38B 18.98B 17.26B 32.45B 2,236B 32.99B 222B 86.95B 1,120B 87.8B 85.89B 3,721B P/E 2026 *
-14.6x
P/E 2027 * -15.2x
Enterprise Value 9.42B 10.9B 8.85B 8.05B 15.13B 1,043B 15.38B 104B 40.54B 522B 40.94B 40.05B 1,735B EV / Sales 2026 *
5.15x
EV / Sales 2027 * 5.77x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.05%
1 week-0.62%
Current month+2.77%
1 month+1.20%
3 months+3.95%
6 months-12.07%
Current year-2.22%
1 week 90.52
Extreme 90.52
94.25
1 month 88.2
Extreme 88.2
94.41
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
388
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%-0.62%-18.00%-11.93% 23.38B
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
+1.12%-1.25%+321.99%+194.89% 12.24B
Average -0.21%+1.63%+79.68%+204.53% 27.59B
Weighted average by Cap. -0.99%+0.47%+62.29%+166.32%

Financials

2026 *2027 *
Net sales 1.83B 2.12B 1.72B 1.56B 2.94B 203B 2.99B 20.15B 7.88B 101B 7.96B 7.78B 337B 1.86B 2.16B 1.75B 1.59B 3B 206B 3.04B 20.53B 8.03B 103B 8.1B 7.93B 343B
Net income -1.34B -1.55B -1.26B -1.15B -2.15B -148B -2.19B -14.76B -5.77B -74.33B -5.83B -5.7B -247B -1.34B -1.55B -1.26B -1.14B -2.15B -148B -2.19B -14.75B -5.77B -74.25B -5.82B -5.7B -247B
Net Debt -10.78B -12.48B -10.13B -9.21B -17.32B -1,193B -17.6B -119B -46.4B -598B -46.86B -45.84B -1,986B -9.44B -10.93B -8.87B -8.07B -15.17B -1,045B -15.42B -104B -40.65B -523B -41.04B -40.15B -1,740B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
14/08/26 US$93.09 +1.05% 650,531
13/08/26 US$92.12 -0.67% 988,541
12/08/26 US$92.74 -0.06% 476,504
11/08/26 US$92.80 0.00% 705,979
10/08/26 US$92.80 -0.93% 731,127
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.40EUR
Average target price
104.26EUR
Spread / Average Target
+29.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock